Literature DB >> 22858859

Imaging in gynecological disease (8): ultrasound characteristics of recurrent borderline ovarian tumors.

D Franchi1, S Boveri, R Fruscio, D Fischerova, S Guerriero, M C Moruzzi, N Colombo, D Timmerman, L Valentin, A C Testa.   

Abstract

OBJECTIVES: To describe the sonographic characteristics of borderline ovarian tumor (BOT) recurrence.
METHODS: From the databases of five ultrasound centers, we retrospectively identified 68 patients with histological diagnosis of recurrent BOT who had undergone preoperative ultrasound examination. All recurrences were detected during planned follow-up ultrasound examinations. Recurrent lesions were described using the terms and definitions of the International Ovarian Tumor Analysis (IOTA) group.
RESULTS: Sixty-two patients had a serous BOT recurrence and six a mucinous BOT recurrence. All patients except one were premenopausal, 84% of them being < 40 years old. All but one patient were asymptomatic at diagnosis of the recurrence. Fertility-sparing surgery of the recurrent tumor was performed in 57/68 (84%) patients. The most frequent ultrasound feature of recurrent serous BOT was a unilocular solid cyst (49/62, 79%) and almost half of the recurrent serous BOTs (29/62, 47%) had multiple papillary projections. In 89% of the recurrent serous BOTs there was at least one papillation with irregular surface and in 73% there was at least one papillation vascularized at color Doppler examination. Recurrent mucinous BOTs appeared mainly as multilocular or multilocular solid cysts (5/6, 83%).
CONCLUSION: Sonographic features of recurrent BOT resemble those described by others for different subtypes of primary BOT.
Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 22858859     DOI: 10.1002/uog.12276

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  6 in total

1.  Oocyte cryopreservation in two women with borderline ovarian tumor recurrence.

Authors:  Francesca Filippi; Fabio Martinelli; Edgardo Somigliana; Dorella Franchi; Francesco Raspagliesi; Valentina Chiappa
Journal:  J Assist Reprod Genet       Date:  2020-03-04       Impact factor: 3.412

2.  Borderline ovarian tumor in pregnancy: can surgery wait? A case series.

Authors:  Ailyn M Vidal Urbinati; Anna D Iacobone; Raffaela C Di Pace; Ida Pino; Maria R Pittelli; Maria E Guerrieri; Eleonora P Preti; Dorella Franchi
Journal:  Arch Gynecol Obstet       Date:  2021-05-05       Impact factor: 2.344

3.  Predictive features of borderline ovarian tumor recurrence in patients with childbearing potential undergoing conservative treatment.

Authors:  Vito Andrea Capozzi; Stefano Cianci; Elisa Scarpelli; Luciano Monfardini; Alessadra Cianciolo; Giuseppe Barresi; Marcello Ceccaroni; Giulio Sozzi; Vincenzo Dario Mandato; Stefano Uccella; Massimo Franchi; Vito Chinatera; Roberto Berretta
Journal:  Mol Clin Oncol       Date:  2022-06-07

Review 4.  Role of ultrasound in the detection of recurrent ovarian cancer: a review of the literature.

Authors:  Andrea Rosati; Salvatore Gueli Alletti; Vito Andrea Capozzi; Mariateresa Mirandola; Virginia Vargiu; Camilla Fedele; Stefano Uccella; Carmine Vascone
Journal:  Gland Surg       Date:  2020-08

Review 5.  Ultrasound evaluation of ovarian masses and assessment of the extension of ovarian malignancy.

Authors:  Francesca Moro; Rosanna Esposito; Chiara Landolfo; Wouter Froyman; Dirk Timmerman; Tom Bourne; Giovanni Scambia; Lil Valentin; Antonia Carla Testa
Journal:  Br J Radiol       Date:  2021-06-09       Impact factor: 3.629

Review 6.  ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.

Authors:  Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2021-06-10       Impact factor: 3.437

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.